Skip to main content

Yumanity Therapeutics, Inc. (YMTX)

NASDAQ: YMTX · IEX Real-Time Price · USD
4.22 -0.16 (-3.65%)
Nov 26, 2021 1:00 PM EST - Market closed

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Year20202019201820172016201520142013
Revenue
6.902.845.348.384.315.151.14
Revenue Growth
---46.83%-36.30%94.43%-16.27%351.36%-
Gross Profit
6.902.845.348.384.315.151.14
Selling, General & Admin
11.887.0615.7111.6611.886.324.093.75
Research & Development
22.3122.9750.3153.6533.9622.5216.7412.98
Other Operating Expenses
28.340000000
Operating Expenses
62.5330.0366.0265.3145.8428.8520.8316.72
Operating Income
-55.63-30.03-63.18-59.97-37.46-24.53-15.68-15.58
Interest Expense / Income
1.91.210000.60.20
Other Expense / Income
-0.04-0.03-1.35-0.54-0.22-0.09-0.110.14
Pretax Income
-57.49-31.21-61.83-59.43-37.23-25.04-15.77-15.72
Net Income
-57.49-31.21-61.83-59.43-37.23-25.04-15.77-15.72
Preferred Dividends
-6.70001.38-1.7313.876.89
Net Income Common
-50.79-31.21-61.83-59.43-38.61-23.31-29.65-22.61
Shares Outstanding (Basic)
22211000
Shares Outstanding (Diluted)
22211000
Shares Change
10.95%10.24%51.51%35.44%3291.31%18.93%10.84%-
EPS (Basic)
-21.57-14.71-32.20-46.80-41.20-842.80-1274.80-1077.40
EPS (Diluted)
-21.57-14.71-32.20-46.80-41.20-842.80-1274.80-1077.40
Free Cash Flow Per Share
-7.72-13.12-30.79-41.34-44.93-711.47-379.73-617.44
Gross Margin
100.00%-100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-806.71%--2224.72%-1122.88%-446.74%-568.97%-304.52%-1365.64%
Profit Margin
-833.63%--2177.18%-1112.75%-444.08%-580.71%-306.25%-1377.74%
Free Cash Flow Margin
-263.50%--2086.58%-983.21%-502.64%-456.35%-171.48%-1135.41%
EBITDA
-52.32-27.89-60.05-58.03-36.93-24.17-15.15-15.11
EBITDA Margin
-758.64%--2114.58%-1086.50%-440.43%-560.51%-294.10%-1324.45%
EBIT
-55.59-30-61.83-59.43-37.23-24.44-15.57-15.72
EBIT Margin
-806.08%--2177.18%-1112.75%-444.08%-566.81%-302.39%-1377.74%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).